Medicare to Cover GLP-1 Weight-Loss Drugs Starting July 1
Qualifying Medicare beneficiaries can access GLP-1 weight-loss medications for $50/month beginning July 1, but experts urge awareness of side effects.
For the first time in the program's history, Medicare beneficiaries who qualify will gain access to GLP-1 weight-loss drugs starting July 1, with out-of-pocket costs capped at $50 per month — a landmark shift in coverage that could affect millions of older Americans struggling with obesity.
The new benefit marks a significant policy change for Medicare, which has historically excluded weight-loss medications from coverage. Eligible seniors who meet the qualifying criteria will now be able to obtain these drugs, which have reshaped the obesity treatment landscape in recent years, at a dramatically lower cost than what the uninsured market typically demands.
Read more Annuities Moving Into 401(k) Plans: What Workers Need to Know →
However, healthcare providers are cautioning new users to weigh the risks alongside the benefits. GLP-1 medications are associated with notable side effects, and one particular concern for older adults is muscle loss — a condition known as sarcopenia that carries heightened risks for seniors, including increased vulnerability to falls and reduced physical function.
Financial and health experts advise Medicare enrollees to consult with their physicians before starting GLP-1 therapy, ensuring they understand both the eligibility requirements and the medical monitoring that responsible use of these powerful drugs demands. For older adults already managing multiple chronic conditions, the interaction profile and long-term implications of sustained GLP-1 use deserve careful discussion with a care team.
Continue reading at MarketWatch.com
